Blinatumomab Assigned Breakthrough Therapy Designation to Treat Acute Lymphoblastic Leukemia

Share this content:

the Cancer Therapy Advisor take:

Amgen has announced that the U.S. Food and Drug Administration (FDA) has designated its drug, blinatumomab, breakthrough therapy status. Blinatumomab is an investigational bispecific T-cell engager (BiTE) antibody currently being studied for the treatment of adults with Philadelphia chromosome-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).


The FDA granted this status based on the results of Amgen's phase 2 trial presented at the American Society of Clinical Oncology (ASCO) annual meeting. In the study, 189 adults with Ph-negative relapsed/refractory B-precursor ALL were treated with blinatumomab.


Of those, 43% experienced a complete response and relapse-free survival duration was 5.9 months. Overall survival duration was 6.1 months. The most common grade 3 adverse events observed were febrile neutropenia, neutropenia, and anemia.


A phase 3 study testing blinatumomab in patients with Ph- ALL is currently underway. According to the American Cancer Society, about 6,000 adults will be diagnosed with ALL in 2014, and nearly 1,500 will die from the disease.

A "Game Changer" in ALL and CLL?
Amgen has announced that the FDA has designated its drug, blinatumomab, Breakthrough Therapy status.
"The results from the Phase 2 trial evaluating blinatumomab in adult patients with relapsed or refractory ALL are encouraging and provide a strong basis for a regulatory filing later this year and potential approval in this serious disease."

The FDA states that Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs